Univariate analysis of response rates according to clinical factors, including the maximal SUV
| . | Total patients . | Responding patients . | Response rate (%) . | P . | ||||
|---|---|---|---|---|---|---|---|---|
| Maximal SUV | ||||||||
| ≤7.5 | 44 | 15 | 34.1 | 0.013 | ||||
| >7.5 | 41 | 25 | 61.0 | |||||
| Sex | ||||||||
| Male | 66 | 28 | 42.4 | 0.111 | ||||
| Female | 19 | 12 | 64.2 | |||||
| Histopathology | ||||||||
| Adenocarcinoma | 38 | 18 | 47.4 | 0.959 | ||||
| Others | 47 | 22 | 46.8 | |||||
| Performance status | ||||||||
| 0 or 1 | 78 | 38 | 48.7 | 0.439 | ||||
| 2 | 7 | 2 | 28.6 | |||||
| Location of the maximal SUV | ||||||||
| Primary tumor | 69 | 32 | 46.4 | 0.794 | ||||
| Other sites | 16 | 8 | 50.0 | |||||
| Disease status | ||||||||
| Locally advanced (stage III) | 21 | 8 | 38.1 | 0.613 | ||||
| Metastatic (stage IV) | 47 | 24 | 51.1 | |||||
| Recurrent after surgery | 17 | 8 | 47.1 | |||||
| Chemotherapy regimens | ||||||||
| Cisplatin based | 64 | 28 | 43.8 | 0.286 | ||||
| Carboplatin based | 21 | 12 | 57.1 | |||||
| . | Total patients . | Responding patients . | Response rate (%) . | P . | ||||
|---|---|---|---|---|---|---|---|---|
| Maximal SUV | ||||||||
| ≤7.5 | 44 | 15 | 34.1 | 0.013 | ||||
| >7.5 | 41 | 25 | 61.0 | |||||
| Sex | ||||||||
| Male | 66 | 28 | 42.4 | 0.111 | ||||
| Female | 19 | 12 | 64.2 | |||||
| Histopathology | ||||||||
| Adenocarcinoma | 38 | 18 | 47.4 | 0.959 | ||||
| Others | 47 | 22 | 46.8 | |||||
| Performance status | ||||||||
| 0 or 1 | 78 | 38 | 48.7 | 0.439 | ||||
| 2 | 7 | 2 | 28.6 | |||||
| Location of the maximal SUV | ||||||||
| Primary tumor | 69 | 32 | 46.4 | 0.794 | ||||
| Other sites | 16 | 8 | 50.0 | |||||
| Disease status | ||||||||
| Locally advanced (stage III) | 21 | 8 | 38.1 | 0.613 | ||||
| Metastatic (stage IV) | 47 | 24 | 51.1 | |||||
| Recurrent after surgery | 17 | 8 | 47.1 | |||||
| Chemotherapy regimens | ||||||||
| Cisplatin based | 64 | 28 | 43.8 | 0.286 | ||||
| Carboplatin based | 21 | 12 | 57.1 | |||||